The US Food and Drug Administration (FDA) has revealed plans to issue new Commissioner’s National Priority Vouchers (CNPVs) to companies “supporting US national interests”.  The new voucher may be redeemed by drug developers to participate in a novel priority programme that shortens drug review time from approximately 10-12 months to one to two months following […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!